Sep 14, 2023 | News, Press Releases
Study met primary and secondary endpoints confirming first Phase 3 study findings MAPP2 population reflects PTSD demographic with approximately half of study participants identifying as racially or ethnically diverse Company on track for NDA filing in 2023 SAN JOSE,...
Jul 6, 2023 | News, Press Releases
Codes will provide qualified healthcare professionals a means to seek reimbursement for delivering MDMA-assisted therapy if it is approved by the U.S. Food and Drug Administration SAN JOSE, Calif., July 6, 2023—MAPS Public Benefit Corporation (“MAPS PBC”), a...
Jun 21, 2023 | News, Press Releases
Agreement underscores benefit of collaboration to accelerate review of new evidence-based treatment options for people with PTSD Submission of new drug application expected in the second half of 2023 SAN JOSE, Calif., June 21, 2023—MAPS Public Benefit Corporation...
May 2, 2023 | News, Press Releases
COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approved London, UK and San Jose, US – May 2, 2023 COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company...
Apr 5, 2023 | News, Press Releases
Interim results show improvements in PTSD symptom severity lasted at least six months after the last treatment session Findings are consistent with previously published Phase 2 data[1] on the sustained effect of MDMA-assisted therapy for the treatment of PTSD SAN...
Jan 19, 2023 | News, Press Releases
Results demonstrate a biological correlation between reduction in PTSD severity and treatment with MDMA-assisted therapy in veterans and first responders Study sheds light on neurological mechanisms that drive MDMA-assisted therapy in PTSD SAN JOSE, Calif.,...
